REFERENCE FILE
Cagrilintide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Investigational
- Evidence category
- Randomized evidence
- Mechanism
- A long-acting amylin analogue.
- Evidence
- A randomized weight-management trial was funded by Novo Nordisk.
- Limitations
- Combination results cannot be assigned to a single ingredient.
- Safety
- The trial reported gastrointestinal and injection-site reactions.
- Formulation and route
- Studied as a subcutaneous injection.
- Approval scope
- Investigational; no FDA-approved product.
A SECOND LOOK
A question to carry into the reading
For cagrilintide, make a small reading key before interpreting any number you encounter. Record the measure’s name, its unit, the reference point, and what an increase or decrease would mean within that measure. If the source uses a percentage, identify what the percentage is of. If a chart and a sentence use different forms, check how they connect before treating them as interchangeable. Leave conversions unfinished when their inputs are unavailable. A careful note should allow someone else to reconstruct what the number describes without relying on the surrounding headline or guessing which unit you intended.
Questions to keep beside the page
- What is the unit, and what does the reported number describe?
- If this is a percentage, where is its reference quantity defined?
- Can I connect the chart and wording without assuming an unstated conversion?
Sources for this file
FROM THE REFERENCE DESK